Age-Related Macular Degeneration: Cost-of-Illness Issues

ISSN： 1170-229X

Source： Drugs & Aging, Vol.18, Iss.4, 2001-04, pp. : 233-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

By Wolowacz Sorrel E.

PharmacoEconomics, Vol. 25, Iss. 10, 2007-01 ,pp. : 863-879

Adis International

Access to resources Recommend Favorite

Economic Cost of Age-Related Macular Degeneration: A Review of Recent Research

By Ke Kathleen M.

Drugs & Aging, Vol. 23, Iss. 3, 2006-01 ,pp. : 217-225

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration

By Mitchell Paul

PharmacoEconomics, Vol. 29, Iss. 2, 2011-02 ,pp. : 107-131

Adis International

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K. Jones Mechelle L. Halpern Michael T.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A. Keating Gillian M.

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite